1-6 of 6
Diwakar Davar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks

Ann W. Silk, Diwakar Davar
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1076–1078.
https://doi.org/10.1158/1078-0432.CCR-23-3320
Published: 15 March 2024
View article titled, Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks
Open the PDF for Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks in another window
Journal Articles

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

Diwakar Davar, Hassane M. Zarour
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4370–4384.
https://doi.org/10.1158/1078-0432.CCR-21-1129
Published: 14 October 2022
View article titled, Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Open the PDF for Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy in another window
Journal Articles

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3990–4002.
https://doi.org/10.1158/1078-0432.CCR-22-0339
Published: 15 September 2022
View article titled, Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Open the PDF for Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4195–4204.
https://doi.org/10.1158/1078-0432.CCR-20-4301
Published: 01 August 2021
View article titled, Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Open the PDF for Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Joe-Marc Chauvin, Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio, Cindy Sanders, Jiajie Hou, Xian-Yang Li, Soldano Ferrone, Diwakar Davar, John M. Kirkwood, Robert J. Johnston, Alan J. Korman, Mark J. Smyth, Hassane M. Zarour
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5520–5533.
https://doi.org/10.1158/1078-0432.CCR-20-0575
Published: 15 October 2020
View article titled, IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Open the PDF for IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux

Diwakar Davar, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5412–5414.
https://doi.org/10.1158/1078-0432.CCR-14-3132
Published: 14 December 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux in another window